All Relations between Alzheimer Disease and microtubule-associated protein tau

Publication Sentence Publish Date Extraction Date Species
Xi Li, Ming Li, Yuan Li, Qiankun Quan, Juan Wan. Cellular and molecular mechanisms underlying the action of ginsenoside Rg1 against Alzheimer's disease. Neural regeneration research. vol 7. issue 36. 2014-10-15. PMID:25317137. these results suggest that ginsenoside rg1 upregulates brain-derived neurotrophic factor expression and inhibits tau protein phosphorylation in brain slices from a rat model of alzheimer's disease. 2014-10-15 2023-08-13 rat
John F Castro-Alvarez, S Alejandro Uribe-Arias, Kenneth S Kosik, Gloria P Cardona-Góme. Long- and short-term CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice. Frontiers in aging neuroscience. vol 6. 2014-10-13. PMID:25309427. long- and short-term cdk5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic alzheimer's mice. 2014-10-13 2023-08-13 mouse
Michael Deuschle, Claudia Schilling, F Markus Leweke, Frank Enning, Thomas Pollmächer, Hermann Esselmann, Jens Wiltfang, Lutz Frölich, Isabella Heuse. Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau. Neuroscience letters. vol 561. 2014-10-07. PMID:24373987. we analyzed aβ40, aβ42, tau protein, phosphorylated tau (ptau) protein as well as hypocretin-1 concentrations in the csf of a detection sample of 10 patients with alzheimer's disease (ad) as well as 10 age- and gender-matched patients with major depression as a comparison group of different pathology. 2014-10-07 2023-08-12 Not clear
Jamie Toombs, Ross W Paterson, Michael P Lunn, Jenifer M Nicholas, Nick C Fox, Miles D Chapman, Jonathan M Schott, Henrik Zetterber. Identification of an important potential confound in CSF AD studies: aliquot volume. Clinical chemistry and laboratory medicine. vol 51. issue 12. 2014-10-06. PMID:23940064. cerebrospinal fluid (csf) amyloid β1-42 (aβ1-42), total tau (t-tau) and phosphorylated tau181 (p-tau) are finding increasing utility as biomarkers of alzheimer's disease (ad). 2014-10-06 2023-08-12 Not clear
Eloi Magnin, Claire Paquet, Maité Formaglio, Bernard Croisile, Ludivine Chamard, Carole Miguet-Alfonsi, Gregory Tio, Julien Dumurgier, Isabelle Roullet-Solignac, Mathilde Sauvée, Catherine Thomas-Antérion, Alain Vighetto, Jacques Hugon, Pierre Vande. Increased cerebrospinal fluid tau levels in logopenic variant of Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 39. issue 3. 2014-10-06. PMID:24217280. increased cerebrospinal fluid tau levels in logopenic variant of alzheimer's disease. 2014-10-06 2023-08-12 Not clear
Sergio Camero, María J Benítez, Alejandro Barrantes, José M Ayuso, Raquel Cuadros, Jesús Avila, Juan S Jiméne. Tau protein provides DNA with thermodynamic and structural features which are similar to those found in histone-DNA complex. Journal of Alzheimer's disease : JAD. vol 39. issue 3. 2014-10-06. PMID:24254705. tau protein has been proposed as a trigger of alzheimer's disease once it is hyperphosphorylated. 2014-10-06 2023-08-12 Not clear
Min-Kyoo Shin, Hong-Gi Kim, Seung-Hyun Baek, Woo-Ram Jung, Dong-Ik Park, Jong-Sung Park, Dong-Gyu Jo, Kil-Lyong Ki. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques. Neurobiology of aging. vol 35. issue 5. 2014-10-06. PMID:24268884. alzheimer's disease (ad) is a neurodegenerative disease characterized by amyloid beta (aβ) deposits, hyperphosphorylated tau deposition, and cognitive dysfunction. 2014-10-06 2023-08-12 mouse
Filipa I Baptista, Ana G Henriques, Artur M S Silva, Jens Wiltfang, Odete A B da Cruz e Silv. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. ACS chemical neuroscience. vol 5. issue 2. 2014-10-06. PMID:24328060. alzheimer's disease is characterized by pathological aggregation of protein tau and amyloid-β peptides, both of which are considered to be toxic to neurons. 2014-10-06 2023-08-12 Not clear
Filipa I Baptista, Ana G Henriques, Artur M S Silva, Jens Wiltfang, Odete A B da Cruz e Silv. Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. ACS chemical neuroscience. vol 5. issue 2. 2014-10-06. PMID:24328060. experimental evidence supports the hypothesis that certain flavonoids may protect against alzheimer's disease in part by interfering with the generation and assembly of amyloid-β peptides into neurotoxic oligomeric aggregates and also by reducing tau aggregation. 2014-10-06 2023-08-12 Not clear
b' Yash B Joshi, Phillip F Giannopoulos, Jin Chu, Domenico Pratic\\xc3\\xb. Modulation of lipopolysaccharide-induced memory insult, \\xce\\xb3-secretase, and neuroinflammation in triple transgenic mice by 5-lipoxygenase. Neurobiology of aging. vol 35. issue 5. 2014-10-06. PMID:24332986.' besides amyloid and tau pathology, a constant feature of alzheimer's disease (ad) is an intense inflammatory response, which is considered an active player in its pathogenesis. 2014-10-06 2023-08-12 mouse
Khalid Iqbal, Cheng-Xin Gong, Fei Li. Microtubule-associated protein tau as a therapeutic target in Alzheimer's disease. Expert opinion on therapeutic targets. vol 18. issue 3. 2014-10-06. PMID:24387228. microtubule-associated protein tau as a therapeutic target in alzheimer's disease. 2014-10-06 2023-08-12 Not clear
Ilie-Cosmin Stancu, Laurence Ris, Bruno Vasconcelos, Claudia Marinangeli, Léonie Goeminne, Vincent Laporte, Laetitia E Haylani, Julien Couturier, Olivier Schakman, Philippe Gailly, Nathalie Pierrot, Pascal Kienlen-Campard, Jean-Noël Octave, Ilse Dewachte. Tauopathy contributes to synaptic and cognitive deficits in a murine model for Alzheimer's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. vol 28. issue 6. 2014-10-06. PMID:24604080. tau alterations are now considered an executor of neuronal demise and cognitive dysfunction in alzheimer's disease (ad). 2014-10-06 2023-08-12 mouse
Masato Hasegawa, Sayuri Watanabe, Hiromi Kondo, Haruhiko Akiyama, David M A Mann, Yuko Saito, Shigeo Murayam. 3R and 4R tau isoforms in paired helical filaments in Alzheimer's disease. Acta neuropathologica. vol 127. issue 2. 2014-09-30. PMID:24212601. 3r and 4r tau isoforms in paired helical filaments in alzheimer's disease. 2014-09-30 2023-08-12 Not clear
Manuela Polydoro, Volodymyr I Dzhala, Amy M Pooler, Samantha B Nicholls, A Patrick McKinney, Laura Sanchez, Rose Pitstick, George A Carlson, Kevin J Staley, Tara L Spires-Jones, Bradley T Hyma. Soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early Alzheimer's disease model. Acta neuropathologica. vol 127. issue 2. 2014-09-30. PMID:24271788. soluble pathological tau in the entorhinal cortex leads to presynaptic deficits in an early alzheimer's disease model. 2014-09-30 2023-08-12 mouse
Julia Banzhaf-Strathmann, Eva Benito, Stephanie May, Thomas Arzberger, Sabina Tahirovic, Hans Kretzschmar, André Fischer, Dieter Edbaue. MicroRNA-125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease. The EMBO journal. vol 33. issue 15. 2014-09-30. PMID:25001178. microrna-125b induces tau hyperphosphorylation and cognitive deficits in alzheimer's disease. 2014-09-30 2023-08-13 mouse
Jillian C Belrose, Raheleh Masoudi, Bernadeta Michalski, Margaret Fahnestoc. Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies. Neurobiology of aging. vol 35. issue 4. 2014-09-29. PMID:24112788. aggregated amyloid-β has been shown to down-regulate specific bdnf transcripts in alzheimer's disease, but the role of tau pathology in neurotrophin dysregulation has not been investigated. 2014-09-29 2023-08-12 human
Jillian C Belrose, Raheleh Masoudi, Bernadeta Michalski, Margaret Fahnestoc. Increased pro-nerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies. Neurobiology of aging. vol 35. issue 4. 2014-09-29. PMID:24112788. these findings implicate tau pathology in neurotrophin dysregulation, which may represent a mechanism through which tau confers toxicity in alzheimer's disease and related non-alzheimer's dementias. 2014-09-29 2023-08-12 human
Timothy J Hohman, Mary Ellen I Koran, Tricia A Thornton-Well. Interactions between GSK3β and amyloid genes explain variance in amyloid burden. Neurobiology of aging. vol 35. issue 3. 2014-09-29. PMID:24112793. the driving theoretical framework of alzheimer's disease (ad) has been built around the amyloid-β (aβ) cascade in which amyloid pathology precedes and drives tau pathology. 2014-09-29 2023-08-12 Not clear
Matthew R Brier, Jewell B Thomas, Anne M Fagan, Jason Hassenstab, David M Holtzman, Tammie L Benzinger, John C Morris, Beau M Ance. Functional connectivity and graph theory in preclinical Alzheimer's disease. Neurobiology of aging. vol 35. issue 4. 2014-09-29. PMID:24216223. alzheimer's disease (ad) has a long preclinical phase in which amyloid and tau cerebral pathology accumulate without producing cognitive symptoms. 2014-09-29 2023-08-12 human
Aaron Carman, Sarah Kishinevsky, John Koren, Wenjie Luo, Gabriela Chiosi. Regulatory chaperone complexes in neurodegenerative diseases: a perspective on therapeutic intervention. Current Alzheimer research. vol 11. issue 1. 2014-09-29. PMID:24251390. these species, called chaperone client proteins, include the pathogenic factors of numerous neurodegenerative disorders, including tau in alzheimer's disease, α-synuclein and lrrk2 in parkinson's disease, sod-1, tdp-43 and fus in amyotrophic lateral sclerosis, and polyq-expanded proteins such as huntingtin in huntington's disease. 2014-09-29 2023-08-12 Not clear